Gender-affirming care or "sex-rejecting procedures"? What the evidence on medical transition for minors shows

Few medical questions are argued as fiercely, or with such different vocabularies. Supporters call puberty blockers, cross-sex hormones and, rarely, surgery for young people with gender dysphoria "gender-affirming care." The US government now calls the same treatments "sex-rejecting procedures," and some critics call blockers "chemical castration." Mediajury uses the plain description and attributes each term to the side that uses it. The question on trial is narrow: what does the evidence actually show, and which popular claims on each side survive it?

Background

Medical transition for adolescents grew out of a Dutch protocol developed in the 1990s and spread widely in the 2010s as referrals rose sharply, especially among adolescent girls. In April 2024 the Cass Review, commissioned by NHS England, concluded that the evidence base for blockers and hormones in under-18s was "remarkably weak" (Reuters). It recommended that blockers be used only within research. In May 2025 the US Department of Health and Human Services published its own evidence review, revised with named contributors and published peer reviews in November 2025. It reached broadly similar conclusions about evidence quality but went further in describing harms. The American Academy of Pediatrics and the Endocrine Society declined HHS invitations to take part in the review, according to the peer review supplement.

Several European health systems have moved to assessment-first models. Sweden, Finland, Norway and Denmark now limit blockers and hormones to exceptional cases or research settings, according to a 2026 overview of Nordic practice. Germany adopted a more cautious consensus guideline in 2025. These are restrictions, not uniform bans.

Where things stand (as of Oct 18, 2026)

• US law. In United States v. Skrmetti (June 18, 2025), the Supreme Court upheld Tennessee's ban on blockers and hormones for minors with gender dysphoria, 6 to 3. The Court applied rational-basis review. It did not decide whether the treatments work.
• US funding. A CMS final rule published Aug 13, 2026 bars federal Medicaid funding for these treatments for under-18s, and CHIP funding for under-19s, from Oct 13, 2026, with a six-month taper for hormones already prescribed. States can still pay with their own money, and New York has told providers to keep billing as usual.
• US medical societies. The American Society of Plastic Surgeons said in February 2026 that gender-related surgery should wait until 19 (position statement, Reuters). The AMA was reported to say surgery should generally be deferred to adulthood (STAT). The AAP's 2018 policy remains in force, and the systematic review it authorised in 2023 had not been published as of this writing.
• UK. Blockers are available only inside the PATHWAYS trial, run by King's College London. The High Court refused a judicial review on July 31, 2026 (judgment, BBC), after the medicines regulator required minimum ages and tighter safety stopping rules (MHRA). In March 2026 NHS England paused new cross-sex hormone prescriptions for under-18s pending consultation (BBC). A final policy is expected this autumn.

Key claims on trial

• "The evidence for blockers and hormones in minors is weak." (critics). Verified. The Cass Review, the HHS review and the Nordic reviews all rate the certainty as low. Most supporters accept the grade and argue that low-certainty evidence is common in pediatrics and is not by itself a reason to withhold care. The dispute is about what to do, not about the grade.
• "Every major medical association supports this care." (supporters). Disputed. Accurate for blockers and hormones with individual assessment (AAP, Endocrine Society). Overstated for surgery, where the plastic surgeons now advise waiting until 19 and the AMA is reported to favour deferral.
• "Puberty blockers are a fully reversible pause button." (supporters). Disputed. Blockers do pause puberty. Full reversibility has not been shown. Cass found insufficient evidence on bone health, cognition and psychosexual development, and the UK trial added stopping rules for bone and cognition.
• "Without this care, young people will die by suicide." (supporters). Unverified. No high-quality study shows these treatments reduce suicide. An independent review for the Department of Health found no rise in suicides after England restricted blockers. A Finnish register study found that higher suicide mortality among gender-referred youth was explained by psychiatric treatment history. Elevated distress in this group is not in dispute.
• "Hormones improve mental health." (supporters). Disputed. Observational studies report improvement, for example a 2023 NEJM study of 315 young people that found depression and anxiety fell over two years (two participants died by suicide). Systematic reviews rate this evidence low certainty because of missing control groups and loss to follow-up.
• "Regret is very rare." (supporters). Disputed. A 2026 systematic review puts median regret around 1 percent. But a 2024 review warns that definitions vary and follow-up is short, and a US military health study found about 30 percent stopped filling hormone prescriptions within four years. Stopping is not the same as regret, and long-term data are thin either way.
• "Europe has banned it." (critics). Disputed. Overstated. The UK, Sweden, Finland, Norway and Denmark have restricted access or limited it to research. That is not a blanket ban across Europe.
• "Blockers are chemical castration that sterilises children." (critics). Disputed. The phrase is rhetoric, not a clinical description. Impaired fertility is a recognised risk, particularly when blockers in early puberty are followed directly by hormones, and the UK trial added fertility information for families. A blanket claim of sterilisation is not established.
• "Most children grow out of gender dysphoria if left alone." (critics). Unverified. The older desistance studies involved younger children under earlier diagnostic criteria and are themselves disputed. They say little about today's adolescent patients.
• "The Supreme Court says these bans are lawful." (critics). Verified. Skrmetti upheld Tennessee's law. Readers should note the ruling was about equal protection, not the medical evidence.
• "The HHS review was a political document." (supporters). Disputed. Several named contributors had published critically on the topic, including people affiliated with the Society for Evidence-Based Gender Medicine and the Manhattan Institute (listed in the report itself). On the other hand, HHS published its peer reviews and replies, including one from the American Psychiatric Association, which is unusually transparent.

What is still unknown

No randomised trial has reported results. Long-term outcomes into adulthood (bone health, fertility, sexual function, mental health, and how many people later detransition) are poorly tracked in every country. Whether the UK PATHWAYS trial can recruit enough participants and keep them in follow-up is an open question. In the US, nobody yet knows how the Medicaid rule will affect access in states that do not backfill with their own funds. The AAP's long-promised evidence review has not appeared.

Source notes

The HHS review and press materials come from an agency that is a party to the policy fight and uses the term "sex-rejecting procedures." They are cited as primary records of its position. The Society for Evidence-Based Gender Medicine (SEGM) is an advocacy organisation critical of pediatric transition, and its explainers are not relied on here. Several claims about the AMA's position rest on STAT's reporting rather than an AMA document. Reports that HHS initially released the review without naming its authors, and that WPATH removed age minimums under political pressure, were not confirmed against primary documents for this story and are not relied on. Some Reuters and BBC details were confirmed from search excerpts because the pages blocked direct retrieval.

Sources

• Cass Review final report (UK Government Web Archive)
• Reuters: Evidence around youth gender care "remarkably weak"
• HHS: Treatment for Pediatric Gender Dysphoria (Nov 2025, party source)
• HHS peer review supplement
• Supreme Court: United States v. Skrmetti
• CMS final rule, Federal Register
• New York DOH provider guidance
• ASPS position statement (2026)
• Reuters: plastic surgeons advise delaying surgery to 19
• STAT: what medical society statements mean
• AAP News: AAP reaffirms policy, authorises review
• BBC: NHS England pauses new cross-sex hormone prescriptions
• BBC: puberty blocker trial can start recruiting
• High Court judgment, Bayswater Support Group v HRA
• MHRA: update on the PATHWAYS trial
• Gran et al., Nordic overview (2026)
• German AWMF guideline (2025, English)
• Appleby review of suicides (GOV.UK)
• Ruuska et al., BMJ Mental Health (2024)
• Chen et al., NEJM (2023)
• Systematic review of discontinuation and regret (2026)
• Journal of Sexual Medicine review of detransition prevalence (2024)
• Roberts et al., JCEM (2022)

Lead image: A demonstrator holds a sign at a rally outside the Georgia State Capitol in Atlanta after lawmakers voted to restrict gender-affirming care for minors, March 20, 2023. Photo: Megan Varner/Reuters, via PBS News.